VTAE up +10.80% percent right now. $VTAE High is at 16.55 and the Low 14.44 with current volume of 172,541.
Recent News posted below.
VTAE Vitae Pharmaceuticals Inc Recent Headline News
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 1 hr 59 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.35 (+1.91), LLY: 67.88 (+1.28), CNCE: 13.60 (+0.50), OPK: 8.57 (+0.25), AZN: 73.24 (+0.36), ALXN: 194.20 (+0.39), ICPT: 178.97 (+6.38), NPSP: 26.82 (-0.67), XLRN: 31.85 (+1.66)
Vitae Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 12, 2014
GlobeNewswire - Wed Nov 05, 5:30PM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, November 12, 2014 at 4:30 p.m. EST to discuss third quarter 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.
VTAE: 16.35 (+1.91)
Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
at The Street - Mon Oct 27, 3:40PM CDT
Birinyi Associates president Laszlo Biriny opined that maybe the economy will catch up and the stock market may not have strong gains going forwardThe stock markets in the United States fluctuated on ...
VTAE: 16.35 (+1.91), AAPL: 108.97 (-0.04), ALXA: 1.63 (-0.04)
Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
GlobeNewswire - Mon Oct 27, 3:10PM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, was approximately $56.0 million.
VTAE: 16.35 (+1.91)
Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
GlobeNewswire - Thu Oct 23, 3:10PM CDT
-- BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels
VTAE: 16.35 (+1.91)
Vitae Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Mon Sep 29, 10:29AM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The aggregate net proceeds to Vitae, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $48.4 million. As previously reported, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 16.35 (+1.91)
CyberArk Soars 60% To Lead Post-IPO Trading Debuts
at Investor's Business Daily - Wed Sep 24, 2:41PM CDT
CyberArk Software soared 60% in first-day trading after its IPO priced above views, leading a group of new issues making their debuts Wednesday. The maker of security software designed to thwart cyberattacks, CyberArk Software (CYBR) priced 5.36...
ICL: 6.88 (-0.08), MDLY: 15.49 (+0.19), SFS: 14.96 (+0.07), JPM: 61.77 (+0.30), CYBR: 34.50 (+1.79), VTAE: 16.35 (+1.91), CFG: 23.96 (-0.01), RBS: 12.00 (+0.10), AAPL: 108.97 (-0.04), BABA: 117.19 (+2.63)
Vitae Pharmaceuticals Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Sep 24, 8:25AM CDT
Vitae Pharmaceuticals, Inc., a clinical stage biotechnology company, today announced the pricing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on September 24, 2014 under the ticker symbol "VTAE." In addition, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 16.35 (+1.91)
Recent News posted below.
VTAE Vitae Pharmaceuticals Inc Recent Headline News
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 1 hr 59 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.35 (+1.91), LLY: 67.88 (+1.28), CNCE: 13.60 (+0.50), OPK: 8.57 (+0.25), AZN: 73.24 (+0.36), ALXN: 194.20 (+0.39), ICPT: 178.97 (+6.38), NPSP: 26.82 (-0.67), XLRN: 31.85 (+1.66)
Vitae Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 12, 2014
GlobeNewswire - Wed Nov 05, 5:30PM CST
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, November 12, 2014 at 4:30 p.m. EST to discuss third quarter 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.
VTAE: 16.35 (+1.91)
Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
at The Street - Mon Oct 27, 3:40PM CDT
Birinyi Associates president Laszlo Biriny opined that maybe the economy will catch up and the stock market may not have strong gains going forwardThe stock markets in the United States fluctuated on ...
VTAE: 16.35 (+1.91), AAPL: 108.97 (-0.04), ALXA: 1.63 (-0.04)
Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
GlobeNewswire - Mon Oct 27, 3:10PM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, was approximately $56.0 million.
VTAE: 16.35 (+1.91)
Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
GlobeNewswire - Thu Oct 23, 3:10PM CDT
-- BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels
VTAE: 16.35 (+1.91)
Vitae Pharmaceuticals Announces Closing of Initial Public Offering
GlobeNewswire - Mon Sep 29, 10:29AM CDT
Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The aggregate net proceeds to Vitae, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $48.4 million. As previously reported, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 16.35 (+1.91)
CyberArk Soars 60% To Lead Post-IPO Trading Debuts
at Investor's Business Daily - Wed Sep 24, 2:41PM CDT
CyberArk Software soared 60% in first-day trading after its IPO priced above views, leading a group of new issues making their debuts Wednesday. The maker of security software designed to thwart cyberattacks, CyberArk Software (CYBR) priced 5.36...
ICL: 6.88 (-0.08), MDLY: 15.49 (+0.19), SFS: 14.96 (+0.07), JPM: 61.77 (+0.30), CYBR: 34.50 (+1.79), VTAE: 16.35 (+1.91), CFG: 23.96 (-0.01), RBS: 12.00 (+0.10), AAPL: 108.97 (-0.04), BABA: 117.19 (+2.63)
Vitae Pharmaceuticals Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Sep 24, 8:25AM CDT
Vitae Pharmaceuticals, Inc., a clinical stage biotechnology company, today announced the pricing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on September 24, 2014 under the ticker symbol "VTAE." In addition, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock to cover over-allotments, if any, at the initial public offering price.
VTAE: 16.35 (+1.91)
